12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gilenya regulatory update

The Scottish Medicines Consortium recommended the restricted use of Novartis' Gilenya fingolimod on the National Health Service (NHS) in Scotland to treat highly active relapsing-remitting multiple sclerosis (RRMS). The consortium recommended Gilenya only as a single disease modifying therapy for...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >